MOTS-c guide
This MOTS-c guide turns on one distinction. There is a large human literature about MOTS-c, and almost none of it involves anyone taking any. It measures the peptide the body already makes8911, or it studies an inherited gene variant that changes it121314. No published study has ever given synthetic MOTS-c to a human being12.
The short answer
- What it is: a sixteen-amino-acid peptide encoded inside mitochondrial DNA rather than in the cell nucleus, which is genuinely unusual biology.
- Human evidence for taking it: none12.
- Animal evidence: real, consistent, and entirely rodents injected into the abdomen51516.
- Pharmacokinetics: none in humans and none in animals either, so there is no half-life figure from any species1.
- A real obstacle: in human blood it is chopped up fast, and nobody has shown an injection produces a useful level7.
- In sport: named on the 2026 prohibited list, banned at all times, with a detection method already built3.
Three different things called “the MOTS-c research”
One: measuring what your body makes. Dozens of studies draw blood, measure MOTS-c, and relate it to insulin sensitivity, exercise, or disease risk. In one, lower levels predicted cardiovascular events over two years8911. These are observations about a natural signal. They cannot tell you what happens if you add more, any more than finding low levels of a hormone in tired people tells you that injecting it fixes tiredness.
Two: an inherited variant. A mitochondrial variant found almost exclusively in East Asian populations produces a less active form of the peptide. Men carrying it had more type 2 diabetes in a study of over 27,000 people, and carriers had more fast-twitch muscle and were over-represented among sprint athletes121314. Interesting genetics. Nobody was given anything.
Three: injecting it. This is what people actually buy, and it exists only in rodents51516.
The Japanese longevity claim, traced
You will meet this claim constantly: that MOTS-c explains Japanese longevity. It has a single source, and the source is a three-page commentary whose title ends in a question mark14.
Its central sentence says that although more research is needed, the authors suggest the variant may be among the putative mechanisms explaining Japanese longevity. That is a hedge inside a hedge inside a suggestion. The piece reports no survival data, follows nobody, and is about an inherited variant rather than about anyone taking MOTS-c.
It is also worth noticing which way the variant evidence actually points: the larger study of the same variant found men who carry it have more diabetes, because the variant makes a less active peptide121314.
What the animal work genuinely shows
The rodent evidence is not weak, and it should not be dismissed. The 2015 paper that discovered MOTS-c found that mice on a high-fat diet treated for eight weeks ended about 20 per cent lighter than untreated mice, and in a clamp measurement — the proper way to measure insulin sensitivity — treated mice needed roughly 30 per cent more glucose to hold their blood sugar steady. In older mice, a week of treatment restored muscle insulin sensitivity towards that of young animals51516.
A later paper found treated mice performed better physically at every age tested, and that starting treatment at 23.5 months increased physical capacity and healthspan6. The osteoporosis and vascular calcification claims that appear in marketing also have rodent studies behind them1817.
Two things to hold alongside that. Every result is a mouse or a rat injected into the abdominal cavity, which is not a route used in people. And FDA points out that across this entire literature nobody assessed dose-response relationships, and the molecular target MOTS-c acts on is still unknown — which makes it hard to predict what organs an injection would even affect15.
The problem nobody has solved
Put MOTS-c into human blood in a laboratory and it is rapidly chopped into shorter fragments, without needing much time at all. The authors of that work state the consequence plainly: it remains to be determined whether giving MOTS-c to a person can generate a useful concentration of the intact peptide over time7.
That is the central unanswered question about this compound, and it cannot be answered by any amount of mouse data. There is no pharmacokinetic study of MOTS-c in humans, and none in animals either1. Any half-life quoted for it comes from nowhere.
There is a measurement problem underneath all of this too. Different studies report blood levels hundreds of times apart, and when a validated laboratory method was compared against a common test kit, it could not reproduce the kit's numbers711. Some of the observational literature may not be measuring the same thing as the rest of it.
What FDA found, and what it flagged
A pharmacy nominated MOTS-c for compounding as an injection, for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism and longevity. FDA declined to evaluate those uses at all, because the nomination gave it too little to work with and it identified no clinical studies of any of them1. An official committee outcome was not identified as of September 20, 2026.
It found no toxicology whatsoever: no acute, repeat-dose, genetic, reproductive or cancer study, in any species1. It judged the substance poorly characterised, with inconsistent naming across commercial products, and said that could mean someone is given a different substance than intended1.
Its specific safety concern is worth understanding because it is unusual. Injecting a peptide the body already makes can prompt an immune response, and antibodies raised against the injected version could in principle also neutralise a person's own MOTS-c12. That is a risk of making things worse, not merely of the treatment not working.
Exercise, and a claim stated more firmly than it should be
Exercise does appear to raise the MOTS-c your body makes. But the best-controlled acute study — 30 people, endurance versus resistance versus control — found a significant rise in a related peptide and only a trend towards a rise in MOTS-c itself, which the authors were careful not to overstate9106.
A longer sixteen-week training programme did find a significant rise, in one ethnic group and not the other. It is worth noting that several of the most-cited papers in this field carry disclosures that authors are consultants and shareholders in a company developing mitochondrial-derived peptides6121310. That is disclosed, not hidden, and it is a reason to read the framing carefully rather than to discard the data.
The one registration, and why it changes nothing
A phase 2a trial is registered, testing MOTS-c injections in adults with prediabetes. It discloses no dose or formulation anywhere in its record, was registered after enrolment was said to have begun, and declares itself not to be an FDA-regulated drug study despite being a phase 2a trial of an injected drug4.
When we looked up everything its sponsor had registered, we found eight entries sharing one hospital, near-identical dates and most of the compounds in this library — one of them titled a mock study, another copying a large trial a different company published years ago. Registries do not check what sponsors submit. We report the entry and place no weight on it.
Where the rest of the detail lives
The interactive library on the homepage carries the fuller reference entry for MOTS-c, including the amounts and handling notes it holds for every compound. That is general reference information, the same for every visitor.
References
These are the sources behind this page, listed so you can read them yourself rather than take our word for it. Animal and laboratory findings do not establish that something works or is safe in people. Doses and protocols shown on a study card are that study's research parameters, not recommendations. PepCaddie does not sell peptides and does not choose a dose for anyone; this is educational material and it does not replace a qualified healthcare professional.
The one registration, and it does not stand up
2026Registered clinical trial
This is the only entry on the whole trial registry that lists MOTS-c as a drug being given to people rather than measured in them. It was registered after enrolment was said to have started, it discloses no amount or formulation anywhere in the record, and it declares itself not to be an FDA-regulated drug study despite being a phase 2a trial of an injected drug.
Limitation: No results, no stated dose, and registered after the fact. There is also a wider problem with the record. This registration needs more scepticism than a registry entry usually gets. The same sponsor has registered eight studies, all at one hospital, nearly all recording the same start date and all the same completion date, covering most of the compounds in this library. One of them carries the words "Mock Study" in its own title, and another reuses the title and internal study code of a large trial a different company completed and published years earlier. Registry entries come from sponsors and are not checked by the registry, so this record is reported here but is not treated as evidence that a trial is really running.
Phase 2a, randomised, quadruple-masked, placebo-controlledView study: The one registration, and it does not stand up
The paper that discovered it
2015Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
The paper that identified MOTS-c as a peptide encoded inside mitochondrial DNA and showed what it does in mice. On a high-fat diet, treated mice ended eight weeks about 20 per cent lighter than untreated ones. In a clamp measurement, treated mice needed roughly 30 per cent more glucose to hold their blood sugar steady, meaning they had become more insulin sensitive. In older mice, a week of treatment restored muscle insulin sensitivity towards that of young animals.
Limitation: Every result in life is in mice injected into the abdominal cavity, which is not a route used in people. FDA notes across this whole literature that dose-response relationships were never assessed and the molecular target is still unknown.
Controlled animal experiments with insulin clamp measurementsView study: The paper that discovered it
Physical performance in mice, and the origin of the ageing claims
2021Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Treated mice ran better at every age tested, and starting treatment late in life increased physical capacity and healthspan. The human part of the same paper is observational: exercise raises the MOTS-c people already make, in muscle and in blood. Those are two different findings and the paper is clear about which is which.
Limitation: The performance results are mice injected into the abdomen. The human component involves no administration at all. Two authors disclose that they are consultants and shareholders in a company developing mitochondrial-derived peptides.
Controlled animal experiments across three age groupsView study: Physical performance in mice, and the origin of the ageing claims
It is broken down rapidly in human blood
2019Laboratory or in-vitro studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Added to human blood, MOTS-c was rapidly chopped into shorter fragments, and did not need long incubation for that to happen. The authors state plainly that it remains to be determined whether giving MOTS-c to a person can produce a useful concentration of the intact peptide over time. That is the central unanswered question about this compound.
Limitation: Blood in a tube, not a person. It cannot show what happens to an injected dose in a living body, only that the peptide is vulnerable in the medium it would have to survive.
Laboratory method development and validationView study: It is broken down rapidly in human blood
Measured, not given: insulin sensitivity
2018Human observational study
Blood levels of the MOTS-c people make naturally were much the same in lean and obese participants, but correlated with two measures of insulin sensitivity. This is the kind of study most often cited as evidence that MOTS-c improves metabolism, and nobody in it was given anything.
Limitation: Ten people per group. The headline that the association held only in lean participants is a subgroup finding in a sample far too small to support it: not reaching significance in ten people is not evidence of absence.
Cross-sectional observational study, no administrationView study: Measured, not given: insulin sensitivity
Measured, not given: after exercise
2021Human observational study
A related mitochondrial peptide rose significantly after endurance cycling. MOTS-c itself showed only a trend towards an increase, which the authors describe as a trend rather than dressing it up. Levels did not correlate with fitness.
Limitation: Ten people per arm, and the MOTS-c result is explicitly not statistically significant. It is cited here because the claim that exercise raises MOTS-c is usually stated more firmly than this study supports.
Randomised exercise study measuring the body’s own peptideView study: Measured, not given: after exercise
Measured, not given: a 16-week exercise programme
2021Human observational study
After sixteen weeks of combined aerobic and resistance training, the body’s own MOTS-c rose significantly in one ethnic group and not in the other. Again, nobody was given MOTS-c.
Limitation: A secondary analysis of a trial not designed to answer this question, with roughly 25 people in each ethnic subgroup, so the difference between them is unpowered. One author discloses being a consultant and shareholder in a company developing these peptides.
Secondary analysis of an exercise trial, no administrationView study: Measured, not given: a 16-week exercise programme
Measured, not given: as a risk marker
2020Human observational study
Lower levels of the body’s own MOTS-c predicted cardiovascular events over two years, alongside two other markers. It is the largest and longest human observation in this dossier, and it is about the peptide as a signal of risk, not as a treatment.
Limitation: The cut-off value that separated higher from lower risk appears to have been derived from the same group it was then tested on. Its absolute concentrations are also hundreds of times higher than another study in this dossier reports, which is a measurement problem rather than a biological one.
Prospective observational study with a validation groupView study: Measured, not given: as a risk marker
The gene variant, and it points the wrong way
2021Human observational study
People carrying a variant that makes a less active form of MOTS-c were studied across three large cohorts. Men with the variant had a higher prevalence of type 2 diabetes, and among them the effect showed up in the least physically active third. In the mouse arm, ordinary MOTS-c improved glucose tolerance and the variant form did not. This is the paper most often invoked as proof MOTS-c is good for metabolism, and nobody was given anything.
Limitation: An association study measuring how common diabetes was, not how often it developed, with sex-specific and activity-tertile findings that are subgroup analyses. One author discloses being a consultant and shareholder in a company developing these peptides.
Genotype association meta-analysis, plus mouse experimentsView study: The gene variant, and it points the wrong way
The athlete study, which is also about the variant
2022Human observational study
Carriers of the variant had a higher proportion of fast-twitch muscle fibres and, among men, stronger leg strength, and the variant was more common in sprint and power athletes than in endurance athletes. The mouse part of the study used an antibody to block the animals’ own MOTS-c, to imitate the variant. No MOTS-c was administered to anyone.
Limitation: The difference in how common the variant was between sprint athletes, controls and endurance athletes spans only a few percentage points, in a single population. It is a genotype association, and the variant is essentially absent outside East Asian ancestry.
Genotype association study across three groupsView study: The athlete study, which is also about the variant
The Japanese longevity idea, which is a question
2015Narrative review
This is the source of the claim that MOTS-c explains Japanese longevity. It is a three-page commentary whose title ends in a question mark and whose central sentence says that although more research is needed, the authors suggest the variant may be among the putative mechanisms. It reports no survival data of its own.
Limitation: A hypothesis piece, not a study. It measures nothing, follows nobody, and concerns an inherited variant rather than anything anyone took.
Short commentary proposing a hypothesisView study: The Japanese longevity idea, which is a question
Blood sugar in obese mice
2019Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Three days of treatment roughly halved blood glucose in mice made obese by diet, and shifted a range of circulating metabolites including a marker of oxidative stress.
Limitation: Three days, in mice, by abdominal injection. A short experiment in a rodent model of diet-induced obesity says nothing about a person.
Controlled animal study with metabolite profilingView study: Blood sugar in obese mice
Weight and fat after ovary removal in mice
2019Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
In mice whose ovaries had been removed, a model of the metabolic changes after menopause, twelve weeks of treatment prevented weight gain and insulin resistance, reduced fat mass and damped an inflammatory response. This is the longest animal treatment in the dossier.
Limitation: A surgical rodent model, injected into the abdomen. It is a model of a specific hormonal state rather than of ordinary weight gain.
Controlled animal study in a surgical modelView study: Weight and fat after ovary removal in mice
Vascular calcification in rats
2020Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Rats given high-dose vitamin D and nicotine to induce calcium deposits in their arteries had less calcification, lower blood pressure and less heart remodelling when treated with MOTS-c at the same time.
Limitation: An aggressive chemically induced model in rats, with treatment given alongside the insult rather than to established disease. One of the nominated uses rests on this kind of work alone.
Controlled animal study in an induced calcification modelView study: Vascular calcification in rats
Bone loss in mice
2019Animal studyNot human evidence
The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.
Injected directly into the skull, MOTS-c reduced particle-induced bone loss and the number of bone-resorbing cells. Blocking the AMPK pathway abolished the effect, which supports the proposed mechanism.
Limitation: Injected into the site itself, in mice, over a week. The osteoporosis claim that appears in the compounding nomination rests on work like this and on cell culture, with nothing in a person.
Controlled animal study with local injectionView study: Bone loss in mice
FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026: MOTS-c-related bulk drug substances. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-21
Read FDA's 2026 review of MOTS-c for compounding at the sourceCertain bulk drug substances for use in compounding that may present significant safety risks. U.S. Food and Drug Administration; 2026.
Official regulatory sourceChecked 2026-09-21
Read FDA's compounding listing for MOTS-c at the sourceThe 2026 Prohibited List, section S4.4.1. World Anti-Doping Agency; 2026.
Official regulatory sourceChecked 2026-09-21
Read WADA's 2026 list names MOTS-c directly at the sourceA phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacodynamics of MOTS-c in adults with prediabetes and overweight or obesity. ClinicalTrials.gov (sponsor: Hudson Biotech); 2026.
Registered clinical trialNCT07505745Checked 2026-09-21
Read The one registration, and it does not stand up at the sourceLee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism; 2015.
Animal studyPMID 25738459 · DOI 10.1016/j.cmet.2015.02.009Checked 2026-09-21
Read The paper that discovered it at the sourceReynolds JC, Lai RW, Woodhead JST, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications; 2021.
Animal studyPMID 33473109 · DOI 10.1038/s41467-020-20790-0Checked 2026-09-21
Read Physical performance in mice, and the origin of the ageing claims at the sourceKnoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry; 2019.
Laboratory or in-vitro studyPMID 30394592 · DOI 10.1002/rcm.8337Checked 2026-09-21
Read It is broken down rapidly in human blood at the sourceCataldo LR, Fernandez-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine; 2018.
Human observational studyPMID 29593067 · DOI 10.1136/jim-2017-000681Checked 2026-09-21
Read Measured, not given: insulin sensitivity at the sourcevon Walden F, Fernandez-Gonzalo R, Norrbom J, et al.. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology; 2021.
Human observational studyPMID 34351816 · DOI 10.1152/japplphysiol.00706.2019Checked 2026-09-21
Read Measured, not given: after exercise at the sourceDieli-Conwright CM, Sami N, Norris MK, et al.. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports; 2021.
Human observational studyPMID 34413391 · DOI 10.1038/s41598-021-96419-zChecked 2026-09-21
Read Measured, not given: a 16-week exercise programme at the sourceIkonomidis I, Katogiannis K, Kyriakou E, et al.. Beta-amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis; 2020.
Human observational studyPMID 32052315 · DOI 10.1007/s11239-020-02060-4 · NCT04027712Checked 2026-09-21
Read Measured, not given: as a risk marker at the sourceZempo H, Kim SJ, Fuku N, et al.. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging; 2021.
Human observational studyPMID 33468709 · DOI 10.18632/aging.202529Checked 2026-09-21
Read The gene variant, and it points the wrong way at the sourceKumagai H, Natsume T, Kim SJ, et al.. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochimica et Biophysica Acta; 2022.
Human observational studyPMID 34728329 · DOI 10.1016/j.bbagen.2021.130048Checked 2026-09-21
Read The athlete study, which is also about the variant at the sourceFuku N, Pareja-Galeano H, Zempo H, et al.. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?. Aging Cell; 2015.
Narrative reviewPMID 26289118 · DOI 10.1111/acel.12389Checked 2026-09-21
Read The Japanese longevity idea, which is a question at the sourceKim SJ, Miller B, Mehta HH, et al.. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports; 2019.
Animal studyPMID 31293078 · DOI 10.14814/phy2.14171Checked 2026-09-21
Read Blood sugar in obese mice at the sourceLu H, Wei M, Zhai Y, et al.. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine; 2019.
Animal studyPMID 30725119 · DOI 10.1007/s00109-018-01738-wChecked 2026-09-21
Read Weight and fat after ovary removal in mice at the sourceWei M, Gan L, Liu Z, et al.. Mitochondrial-derived peptide MOTS-c attenuates vascular calcification and secondary myocardial remodeling via AMPK signaling pathway. Cardiorenal Medicine; 2020.
Animal studyPMID 31694019 · DOI 10.1159/000503224Checked 2026-09-21
Read Vascular calcification in rats at the sourceYan Z, Zhu S, Wang H, et al.. MOTS-c inhibits osteolysis in the mouse calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacological Research; 2019.
Animal studyPMID 31369811 · DOI 10.1016/j.phrs.2019.104381Checked 2026-09-21
Read Bone loss in mice at the source